Abstract: Provided are highly conserved antigens and epitopes of HIV that can be used in vaccines and to produce bindings proteins (e.g., antibodies) for detecting, treating, preventing, or reducing the risk of HIV infection and the development of AIDS.
Abstract: Disclosed is a human monoclonal antibody produced by the hybridoma designated Clone 3 and having A.T.C.C. Accession No. CRL 10198. The Clone 3 human monoclonal antibody immunologically binds to a conserved epitope on the transmembrane envelope glycoprotein gp41 of Human Immunodeficiency Virus Type 1 (HIV-1) having the amino acid sequence GCSGKLIC.
Abstract: A method for neutralizing HIV-1 is disclosed. A preferred embodiment utilizes a novel human monoclonal antibody that binds to a conserved region of the gp41 transmembrane subunit of the virus. The antibody is produced by continuous cell lines developed using human B lymphocyte cells collected from a patient possessing high titers of anti-HIV antibodies. The conserved region bound by the neutralizing antibody is a peptide of approximately 12 amino acids in length. Similar regions on HIV-2 and SIV are also disclosed.
Abstract: A method for neutralizing the retrovirus Human Immunodeficiency Virus-1 (HIV-1) through free virus neutralization or fusion inhibition, comprises adding to a cell mixture of HIV-infected and uninfected cells, a neutralizing agent which specifically binds to at least a portion of the amino acid sequence R-Leu-Ile-Cys-R', where R is either absent or a sequence of 1 to 5 amino acids selected from the group consisting of Lys, Gly-Lys, Ser-Gly-Lys, Cys-Ser-Gly-Lys and Gly-Cys-Ser-Gly-Lys, and R' is either absent or a sequence of 1 to 2 amino acids selected from the group consisting of Thr and Thr-Thr, under conditions effective for allowing said neutralizing agent to inhibit fusion between said HIV-1 infected cells or free HIV-1 and said uninfected cells or administering the neutralizing agent orally, intravenously, or intramuscularly under conditions effective for allowing said neutralizing agent to inhibit fusion between HIV-1 infected cells and uninfected cells.
Abstract: A method for neutralizing HIV-1 is disclosed. A preferred embodiment utilizes a novel human monoclonal antibody that binds to a conserved region of the gp41 transmembrane subunit of the virus. The antibody is produced by continuous cell lines developed using human B lymphocyte cells collected from a patient possessing high titers of anti-HIV antibodies. The conserved region bound by the neutralizing antibody is a peptide of approximately 12 amino acids in length and preferably 8-10 amino acids. Similar regions on HIV-2 and SIV are also disclosed. The present invention is further directed to a kit and a method for detecting the presence and determining concentration of an antibody that inhibits HIV-1 fusion-associated epitope, a peptide on gp41 with the amino acid sequence represented by GCSGKLIC. The detection and quantitation method includes an enzyme-linked immunosorbent assay (ELISA).